Australia's most trusted
source of pharma news
Tuesday, 17 February 2026
Posted 17 February 2026 AM
A market-disrupting treatment allowing much easier administration for people with a life-threatening condition, has landed in Australia on private script as it waits for a reimbursement decision.
CSL Seqirus' epinephrine nasal spray neffy is now available in Australia for the emergency treatment of anaphylaxis in adults and children weighing more than 15kg and older than four years of age.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.